



Universiteit  
Leiden  
The Netherlands

## **The clinical pharmacology of performance enhancement and doping detection in sports**

Heuberger, J.

### **Citation**

Heuberger, J. (2019, May 16). *The clinical pharmacology of performance enhancement and doping detection in sports*. Retrieved from <https://hdl.handle.net/1887/73419>

Version: Not Applicable (or Unknown)

License: [Leiden University Non-exclusive license](#)

Downloaded from: <https://hdl.handle.net/1887/73419>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/73419> holds various files of this Leiden University dissertation.

**Author:** Heuberger, J.

**Title:** The clinical pharmacology of performance enhancement and doping detection in sports

**Issue Date:** 2019-05-16

## LIST OF PUBLICATIONS

**Heuberger JA**, Cohen Tervaert JM, Schepers FM, Vliegenthart AD, Rotmans JI, Daniels JM, Burggraaf J, Cohen AF. Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit. *Br J Clin Pharmacol* 2013; 75: 1406-21.

**Heuberger J**, Schmidt S, Derendorf H. When is protein binding important? *J Pharm Sci* 2013; 102: 3458-67.

Sy SK, **Heuberger J**, Shilbayeh S, Conrado DJ, Derendorf H. A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation. *AAPS J* 2013; 15: 1189-99.

Kleinloog D, Stevens J, **Heuberger J**, Spinhoven P, van GJ. The influence of personality on the sensitivity to subjective effects of Delta9-tetrahydrocannabinol. *Psychiatry Res* 2014; 220: 945-53.

**Heuberger JA**, Guan Z, Oyetayo OO, Klumpers L, Morrison PD, Beumer TL, van Gerven JM, Cohen AF, Freijer J. Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics. *Clin Pharmacokinet* 2015; 54: 209-19.

Vilums M, **Heuberger J**, Heitman LH, IJzerman AP. Indanes-Properties, Preparation, and Presence in Ligands for G Protein Coupled Receptors. *Med Res Rev* 2015; 35: 1097-126.

Guan Z, Klumpers LE, Oyetayo OO, **Heuberger J**, van Gerven JM, Stevens J. Pharmacokinetic/pharmacodynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Delta(9)-tetrahydrocannabinol challenge tests. *Br J Clin Pharmacol* 2016; 81: 713-23.

Peters E, \***Heuberger JA**\*, Tiessen R, van EA, Masereeuw R, Arend J, Stevens J, Pickkers P. Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy Volunteers. *Clin Pharmacokinet* 2016; 55: 1227-37.

Sy SK, Beaudoin ME, Zhuang L, Loblein KI, Lux C, Kissel M, Tremmel R, Frank C, Strasser S, **Heuberger JA**, Mulder MB, Schuck VJ, Derendorf H. In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms. *J Antimicrob Chemother* 2016; 71: 1866-80.

**Heuberger J**, Rotmans JI, Gal P, Stuurman FE, van 't Westende J, Post TE, Daniels JMA, Moerland M, van Veldhoven PLJ, de Kam ML, Ram H, de Hon O, Posthuma JJ, Burggraaf J, Cohen AF. Effects of erythropoietin on cycling performance of well trained cyclists: a double-blind, randomised, placebo-controlled trial. *Lancet Haematol* 2017; 4: e374-e86.

van Amerongen G, Kanhai K, Baakman AC, **Heuberger J**, Klaassen E, Beumer TL, Strijers RL, Killestein J, van Gerven J, Cohen A, Groeneveld GJ. Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Delta9-Tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis. *Clin Ther* 2017.

**Heuberger J**\*, van Dijkman SC\*, Cohen AF. Futility of current urine salbutamol doping control. *Br J Clin Pharmacol* 2018.

Kovalchuk MO\*, **Heuberger JA**\*, Sleutjes BT, Ziagos D, van de Berg LH, Ferguson TA, Franssen H, Groeneveld GJ. Acute effects of riluzole and retigabine on axonal excitability in patients with ALS: A randomized, double-blind, placebo-controlled, cross-over trial. *Clin Pharmacol Ther* 2018.

Muehlan C, **Heuberger J**, Juif PE, Croft M, van Gerven J, Dingemans J. Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study. *Clin Pharmacol Ther* 2018.

**Heuberger J**, Cohen AF. Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects. *Sports Med* 2018.

**Heuberger J**, Gal P, Stuurman FE, de Muinck Keizer WAS, Mejia Miranda Y, Cohen AF. Repeatability and predictive value of lactate threshold concepts in endurance sports. *PLoS One* 2018; 13: e0206846.

Birkhoff WAJ, **Heuberger J**, Post TE, Gal P, Stuurman FE, Burggraaf J, Cohen AF. Recombinant human erythropoietin does not affect several microvascular parameters in well-trained cyclists. *Physiol Rep* 2018; 6: e13924.

Kletzl H, Marquet A, Gunther A, Tang W, **Heuberger J**, Groeneveld GJ, Birkhoff W, Mercuri E, Lochmuller H, Wood C, Fischer D, Gerlach I, Heinig K, Bugawan T, Dziadek S, Kinch R, Czech C, Khwaja O. The oral splicing modifier RC7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy. *Neuromuscul Disord* 2019; 29: 21-29.

## CURRICULUM VITAE

Jules Heuberger was born on March 15<sup>th</sup>, 1989 in Maastricht, The Netherlands. After completing secondary school at the *Trichter College / Bonnefanten College* in Maastricht in 2007, he studied Bio-Pharmaceutical Sciences at Leiden University. He halted his studies for one year to take the position of Commissioner of General Affairs of the Royal Dutch Pharmacy Student Association (K.N.P.S.V.) in 2009. During his master's he performed a pharmacometrics internship at the Centre for Human Drug Research (CHDR) and an internship at the department of Pharmaceutics of the University of Florida in Gainesville, Florida, us. He obtained his doctoral degree (*cum laude*) in 2013 and started working as a clinical scientist at CHDR. In this position under supervision of dr. G.J. Groeneveld his focus was on clinical studies related to disorders of the central nervous system, with a special interest in neuromuscular disorders. During this period at CHDR he also performed the research described in this thesis under supervision of prof. dr. A.F. Cohen. Since 2018 he holds a position as senior clinical scientist at CHDR in the neurology and pain group. In 2019 he became a board certified clinical pharmacologist. Jules lives together with his partner Evelien.

